Drawing for TRUVERIS

USPTO serial 88791177

TRUVERIS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
Examiner
STURMAN, MELISSA M
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with TRUVERIS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Edmund J. Ferdinand, III

Edmund J. Ferdinand, III FERDINAND IP LLC1221 POST ROAD EASTSUITE 302WESTPORT, CT 06880

Goods and services

ClassDescriptionStatusFirst use
035Business research and consulting services in the field of pharmacy, prescription drug pricing, pharmacy benefit plan design, compiling and analyzing statistics, data and other sources of information for business purposes; data analytics, namely, business data analysis; conducting analysis of market research data and statistics all with respect to periodic fluctuations in drug prices and drug spending and the pharmaceutical industry; retail pharmacy services; promoting, advertising and marketing coupons, discounts cards, rebates and general information of others in the field of prescription drug pricing and pharmacy benefit management; promoting the goods and services of others by providing a website featuring coupons, rebates, price-comparison information, links to the retail web sites of others, and discount information all concerning the purchase of prescription drugsACTIVE
041On-line journals, namely, blogs featuring information on drug pricing, drug spending of patients, and the pharmaceutical industryACTIVE
042Providing a secure electronic online system and providing temporary use of on-line non-downloadable mobile applications featuring technology which allows individuals or entities to access and review prescription plan information and competitive bidding information between prescription benefit plan managers (PBMs) desirous of contracting new plans and businesses, access information relating to prescription services offered by PBMs, and engage in competitive bids to win prescription benefit plan business; providing a website featuring non-downloadable software for reporting, comparing, modeling, analyzing, tracking, benchmarking and monitoring data in the field of pharmacy benefit management; providing a web site featuring technology that enables users to search and print discount coupons, co-pay cards and vouchers for prescription drugs, determine prescription drug prices; providing a web site featuring technology that enables users to analyze, determine and compare the different copays and purchase options for various prescription drugs, locate and determine in-network pharmacy locations, and to record, track, monitor and analyze patient adherence to prescription drug regimens and access awards for patient compliance and adherence to such regimensACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Mar 8, 2021MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 8, 2021ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Aug 4, 2020NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jun 9, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 9, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 20, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 7, 2020PREVLAW OFFICE PUBLICATION REVIEW COMPLETED
May 6, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
May 6, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED
May 6, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
May 5, 2020ALIEASSIGNED TO LIE
May 1, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 1, 2020GEANNOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
May 1, 2020GEAPEXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
May 1, 2020EPENCOMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
May 1, 2020CPEAEXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Apr 29, 2020DOCKASSIGNED TO EXAMINER
Feb 14, 2020MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED
Feb 13, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 13, 2020NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance